Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Garnier’s Vision: GSK To Be “The Most R&D Intensive Company In The World”

Executive Summary

GlaxoSmithKline appears ready to turn the typical pharmaceutical company business model on its head, with plans to significantly increase the percentage of sales spent on research & development and reduce spending on selling, general & administrative expenses

You may also be interested in...



GlaxoSmithKline Selects European Head Witty To Succeed Garnier As CEO

GlaxoSmithKline's incoming CEO Andrew Witty - the current president of European pharmaceuticals -brings to the post experience with cost-effectiveness that could prove an asset as comparative and cost-effectiveness become increasingly important to the U.S pharmaceutical industry

GlaxoSmithKline Selects European Head Witty To Succeed Garnier As CEO

GlaxoSmithKline's incoming CEO Andrew Witty - the current president of European pharmaceuticals -brings to the post experience with cost-effectiveness that could prove an asset as comparative and cost-effectiveness become increasingly important to the U.S pharmaceutical industry

Aranesp Bad Luck Catches Up To Amgen, Forces Pharma-Style Reorganization

As Amgen enters into a major restructuring effort that will include extensive cost-cutting and significant headcount reductions, it will also make serious adjustments to its R&D program - including scaling back from its industry-leading approach of investing a high percentage of sales on R&D

Related Content

UsernamePublicRestriction

Register

PS047386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel